Tilray Brands, Inc. (TLRY) stock
TLRYNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026Score 11/3086% below fair value
$2.43−0.06 (-2.41%)
Close on Nov 13, 2026Market cap $359.12MP/E –Yield –
Tilray Brands total assets
Total assets on the balance sheet at the end of each period.
Tilray Brands's total assets was $2.33B at Aug 31, 2026. For fiscal 2026 it was $2.33B, up 12.2% from the year before. The highest annual figure on record is $5.45B in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | $2.33B | +12.2% |
| FY2025 | May 31, 2025 | $2.07B | -50.9% |
| FY2024 | May 31, 2024 | $4.22B | -2.0% |
| FY2023 | May 31, 2023 | $4.31B | -21.0% |
| FY2022 | May 31, 2022 | $5.45B | +508.0% |
| FY2019 | Dec 31, 2019 | $896.33M | +36.5% |
| FY2018 | Dec 31, 2018 | $656.67M | +1117.2% |
| FY2017 | Dec 31, 2017 | $53.95M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | $2.33B | +11.8% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $2.33B | +12.2% |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | $2.07B | -50.5% |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | $2.10B | -50.8% |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $2.08B | -50.7% |
| Q4 FY2025CQ2 2025 | May 31, 2025 | $2.07B | -50.8% |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | $4.19B | -3.2% |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | $4.26B | -3.2% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $4.22B | -2.0% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | $4.21B | -3.7% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $4.33B | -20.9% |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $4.40B | -21.3% |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $4.31B | -21.0% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $4.38B | -24.8% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | $5.47B | -5.0% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $5.59B | -6.6% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $5.45B | +508.0% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $5.82B | +459.5% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $5.76B | +462.8% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $5.99B | +456.0% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $896.33M | +36.5% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $1.04B | +364.8% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $1.02B | +861.8% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $1.08B | +1895.6% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $656.67M | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $223.80M | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $106.48M | – |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $53.95M | – |
See a number that looks wrong?